The biopharma company completes enrollment of 239 patients for its late-stage study, targeting early 2027 data readout.
Veru Inc. has finalized enrollment for its PLATEAU trial, reaching 239 patients, and plans an interim analysis in Q1 2027. The milestone accelerates the timeline for potential data on the therapy’s efficacy and safety.
The trial focuses on a late-stage clinical program, with prior updates indicating steady progress. Management previously guided for a 2027 readout, aligning with industry expectations for pivotal study timelines.
Shares showed limited immediate reaction, reflecting investor focus on upcoming data rather than enrollment milestones.